The Motley Fool
17 Nov 2026, 21:45 UTC · 4h ago
Biogen: 3 Key Takeaways for Long-Term Investors
Impact · against what's priced in
The reported core revenue growth and Apellis integration are already reflected in Biogen's valuation, which assumes a modest growth path. While the momentum in the rare disease franchise is positive, it does not fundamentally shift the market's primary focus on the LEQEMBI autoinjector and the MS portfolio decline.
- BIIB+0.05
Already priced in
- The price assumes
a modest overall revenue growth path of roughly 4.7% annually
The reported $2 billion in Q3 core pharma revenue and the $1 billion run-rate from Apellis assets align with the growth targets the market already expects.
What BIIB's price assumes · Sep 10





